BioBiz Buzz
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.
Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Disclaimer
https://biobizbuzz.com/disclaimer/
Podcasting since 2025 • 8 episodes
BioBiz Buzz
Latest Episodes
8. Revolutionizing Cancer Drug Development with AI: How BioCopy is Using Physics to Rewrite the Rules of Biotech
By 2040, the World Health Organization predicts that one in two people will be diagnosed with cancer in their lifetime. Yet the traditional pharmaceutical industry remains trapped in a devastating cycle: developing next-generation cancer drugs ...
•
Episode 8
•
19:40
7. Exploring new possibilities in reproductive medicine
ReproNovo demonstrated continued investor interest in the area of reproductive medicine by closing a $65 million Series A round earlier this year. In this episode, ReproNovo’s CEO and co-founder Jean Duvall joins your host, Cormac Sheridan, to ...
•
Episode 7
•
28:24
6. Device Intelligence: How AI and Data Are Powering MedTech’s Next Frontier
In this episode of BioBiz Buzz, your host Shani Alexander is joined by Werner Lanthaler, founder and CEO of WLan Holding, to chart the seismic transformation underway in medical technology. Discover how the convergence of multi-omic diagnostics...
•
Season 1
•
29:44
5. Breaking New Ground in Pain Management with Non-Addictive Opioid Alternatives
As the opioid crisis continues to devastate communities worldwide, millions suffering from chronic and neuropathic pain face a critical dilemma: enduring debilitating pain or risking addiction with traditional opioid medications. In this episod...
•
Season 1
•
21:18
4. The Power of International Alliances: Unpacking the Swiss Biotech Report 2025
In 2024, despite a challenging global financial climate, Switzerland’s biotech sector showed remarkable resilience, maintaining steady revenues of CHF 7.2 billion while achieving a 22% increase in capital investment.In this episode of Bi...
•
Season 1
•
26:01
